Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Summary

This phase II trial studies how well epacadostat and pembrolizumab work in treating participants with pancreatic cancer that has spread to other places in the body. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving epacadostat and pembrolizumab may work better in treating participants with pancreatic cancer.

Timeline

Start

2019-07-31

Primary completion

2020-04-30

Completion

2021-04-30

Drugs

Indications